Recent Quotes (30 days)

You have no recent quotes
chg | %

CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
-0.04 (-0.95%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.14 - 4.23
52 week 3.07 - 6.48
Open 4.19
Vol / Avg. 41,947.00/60,136.00
Mkt cap 116.26M
P/E     -
Div/yield     -
EPS -2.53
Shares 28.21M
Beta 0.73
Inst. own 24%
Aug 2, 2017
Q2 2017 CTi Biopharma Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 3, 2017
Q1 2017 CTi Biopharma Corp Earnings Call - Webcast
May 3, 2017
Q1 2017 CTi Biopharma Corp Earnings Release
Mar 14, 2017
CTi Biopharma Corp at ROTH Conference - Webcast
Mar 2, 2017
Q4 2016 CTi Biopharma Corp Earnings Call
Mar 2, 2017
Q4 2016 CTi Biopharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -2643.90% -92.24%
Operating margin -2562.33% -85.64%
EBITD margin - -84.19%
Return on average assets -147.39% -50.91%
Return on average equity -1846.31% -159.17%
Employees 100 -
CDP Score - -


3101 Western Ave Ste 600
SEATTLE, WA 98121-3047
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Adam R. Craig M.D. Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Bruce J. Seeley Principal Financial Officer, Executive Vice President, Chief Commercial and Administrative Officer, Secretary
Age: 53
Bio & Compensation  - Reuters
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 72
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 43
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 48
Bio & Compensation  - Reuters
Richard L. Love Director
Age: 73
Bio & Compensation  - Reuters
Michael A. Metzger Director
Age: 45
Bio & Compensation  - Reuters
Matthew Perry Director
Bio & Compensation  - Reuters